DK2089711T3 - Fremgangsmåder og sammensætninger til detektion af receptor-ligand-mimetika - Google Patents

Fremgangsmåder og sammensætninger til detektion af receptor-ligand-mimetika

Info

Publication number
DK2089711T3
DK2089711T3 DK07822465.6T DK07822465T DK2089711T3 DK 2089711 T3 DK2089711 T3 DK 2089711T3 DK 07822465 T DK07822465 T DK 07822465T DK 2089711 T3 DK2089711 T3 DK 2089711T3
Authority
DK
Denmark
Prior art keywords
receptor
compositions
detection
methods
ligand mimetics
Prior art date
Application number
DK07822465.6T
Other languages
English (en)
Inventor
Vladimir Khazak
Lutz Weber
Original Assignee
Alphaptose Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphaptose Gmbh filed Critical Alphaptose Gmbh
Application granted granted Critical
Publication of DK2089711T3 publication Critical patent/DK2089711T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DK07822465.6T 2006-11-10 2007-11-09 Fremgangsmåder og sammensætninger til detektion af receptor-ligand-mimetika DK2089711T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85803306P 2006-11-10 2006-11-10
PCT/EP2007/062177 WO2008055995A2 (en) 2006-11-10 2007-11-09 Methods and compositions for detecting receptor ligand mimetics

Publications (1)

Publication Number Publication Date
DK2089711T3 true DK2089711T3 (da) 2012-11-26

Family

ID=39233051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07822465.6T DK2089711T3 (da) 2006-11-10 2007-11-09 Fremgangsmåder og sammensætninger til detektion af receptor-ligand-mimetika

Country Status (9)

Country Link
US (1) US8324188B2 (da)
EP (1) EP2089711B1 (da)
JP (1) JP5773569B2 (da)
CN (1) CN101606061B (da)
AU (1) AU2007316587B2 (da)
CA (1) CA2669012C (da)
DK (1) DK2089711T3 (da)
ES (1) ES2393762T3 (da)
WO (1) WO2008055995A2 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2910332A1 (en) * 2013-04-29 2014-11-06 Apogenix Gmbh Method of diagnosing cancer
CN104133063B (zh) * 2014-06-09 2016-01-06 浙江省海洋水产研究所 一种河豚毒素检测试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2619686C2 (de) 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
DE3530767A1 (de) 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
DE3918082A1 (de) 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
US5149527A (en) 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
AU2545697A (en) 1996-03-27 1997-10-17 Uab Research Foundation Novel uses of phospholipase c inhibitors
DE19822509A1 (de) * 1998-05-19 1999-11-25 Medmark Pharma Gmbh Edelfosin zur Behandlung von Hirntumoren
JP5854184B2 (ja) 2010-03-02 2016-02-09 セイコーエプソン株式会社 液体噴射ヘッド、液体噴射装置、圧電素子、超音波センサー及び赤外センサー

Also Published As

Publication number Publication date
WO2008055995A3 (en) 2008-10-16
JP2010508836A (ja) 2010-03-25
CA2669012C (en) 2017-06-20
JP5773569B2 (ja) 2015-09-02
CN101606061B (zh) 2014-01-22
EP2089711B1 (en) 2012-09-12
CA2669012A1 (en) 2008-05-15
AU2007316587A1 (en) 2008-05-15
US20100111930A1 (en) 2010-05-06
ES2393762T3 (es) 2012-12-27
CN101606061A (zh) 2009-12-16
AU2007316587B2 (en) 2013-10-31
EP2089711A2 (en) 2009-08-19
WO2008055995A2 (en) 2008-05-15
US8324188B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2124999T3 (da) Activin-actrii antagonister og anvendelser til behandling af anæmi
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2063907T3 (da) Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
DK1937824T3 (da) Sammensætninger af tRNA og anvendelser deraf
DE602007010533D1 (de) Bildschirmstandfuß
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1904504T3 (da) Inhibitorer af vegf-receptor- og hgf-receptorsignalering
DK2902690T3 (da) Anomalidetektor til rørledninger
DE602006020394D1 (de) Objektdetektion
DE602006008266D1 (de) Klemm- und Gelenkelement
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
DE602007008788D1 (de) Bildschirmstandfuß
DK1907748T3 (da) Rørforbindelse
FR2901817B1 (fr) Pont temporaire
ITRM20060613A1 (it) Treppiede perfezionato
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK1986508T3 (da) Fremgangsmåder og sammensætninger til behandling af felin hyperthyroidisme
DK2029561T3 (da) Tricyclisk forbindelse og farmaceutisk anvendelse deraf
DK2262525T3 (da) Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme
DK2416157T3 (da) Fremgangsmåde og sammensætninger til specifik påvisning af fysiologisk acceptable polymermolekyler